CD80 and hematopoietic and lymphoid system neoplasm: In addition to solid cancers, we also identified a number of hematological malignancies that co-express high levels of CD80 and PTK2, highlighting potential opportunities for the development of FAK inhibitors for the treatment of some blood cancers.